Tags

Type your tag names separated by a space and hit enter

Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.

Abstract

OBJECTIVE

To evaluate the outcome of repeated intravitreal injections of triamcinolone acetonide for the treatment of exudative age-related macular degeneration.

METHODS

This prospective, comparative nonrandomized clinical interventional study included 13 patients with progressive exudative age-related macular degeneration with occult, or predominantly occult, subfoveal neovascularization. All patients had shown an increase or stabilization of visual acuity after a first intravitreal injection of 25 mg of triamcinolone acetonide. They received a second intravitreal injection of 25 mg of triamcinolone acetonide 3.1 to 18 months after the first injection. Mean +/- SD follow-up time after the second injection was 5.2 +/- 3.6 months (median, 5.3 months). A control group included 24 patients with exudative age-related macular degeneration who did not receive treatment for their maculopathy. The main outcome measures were visual acuity and intraocular pressure.

RESULTS

In the study group, mean +/- SD visual acuity increased significantly (P =.005 and P =.003, respectively) from 0.17 +/- 0.11 to 0.32 +/- 0.26 and from 0.15 +/- 0.14 to 0.23 +/- 0.19, respectively, after the first and second injections. An increase in visual acuity was found for 10 patients (77%) after the first and second injections. In the control group, visual acuity did not vary significantly during follow-up (P =.81). The difference in change in visual acuity between the study group and control group was significant (P =.01 [Snellen lines] and P =.05 [logMAR units]). The peak in visual acuity and, in a chronologically parallel manner, the peak in intraocular pressure elevation occurred 2 to 5 months after each injection.

CONCLUSIONS

Repeated intravitreal injection of 25 mg of triamcinolone acetonide may lead to an increase in visual acuity in patients with exudative age-related macular degeneration, with the peak in visual acuity and intraocular pressure elevation occurring about 2 to 5 months after each injection.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Ophthalmology, Faculty of Clinical Medicine of Mannheim, University of Heidelberg, Heidelberg, Germany. Jost.Jonas@ma.augen.uni-heidelberg.de

    , , ,

    Source

    MeSH

    Aged
    Aged, 80 and over
    Choroidal Neovascularization
    Exudates and Transudates
    Female
    Glucocorticoids
    Humans
    Injections
    Intraocular Pressure
    Macular Degeneration
    Male
    Middle Aged
    Prospective Studies
    Treatment Outcome
    Triamcinolone Acetonide
    Visual Acuity
    Vitreous Body

    Pub Type(s)

    Clinical Trial
    Comparative Study
    Journal Article

    Language

    eng

    PubMed ID

    14769599

    Citation

    Jonas, Jost B., et al. "Intravitreal Reinjection of Triamcinolone for Exudative Age-related Macular Degeneration." Archives of Ophthalmology (Chicago, Ill. : 1960), vol. 122, no. 2, 2004, pp. 218-22.
    Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004;122(2):218-22.
    Jonas, J. B., Akkoyun, I., Budde, W. M., Kreissig, I., & Degenring, R. F. (2004). Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Archives of Ophthalmology (Chicago, Ill. : 1960), 122(2), pp. 218-22.
    Jonas JB, et al. Intravitreal Reinjection of Triamcinolone for Exudative Age-related Macular Degeneration. Arch Ophthalmol. 2004;122(2):218-22. PubMed PMID: 14769599.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. AU - Jonas,Jost B, AU - Akkoyun,Imren, AU - Budde,Wido M, AU - Kreissig,Ingrid, AU - Degenring,Robert F, PY - 2004/2/11/pubmed PY - 2004/3/3/medline PY - 2004/2/11/entrez SP - 218 EP - 22 JF - Archives of ophthalmology (Chicago, Ill. : 1960) JO - Arch. Ophthalmol. VL - 122 IS - 2 N2 - OBJECTIVE: To evaluate the outcome of repeated intravitreal injections of triamcinolone acetonide for the treatment of exudative age-related macular degeneration. METHODS: This prospective, comparative nonrandomized clinical interventional study included 13 patients with progressive exudative age-related macular degeneration with occult, or predominantly occult, subfoveal neovascularization. All patients had shown an increase or stabilization of visual acuity after a first intravitreal injection of 25 mg of triamcinolone acetonide. They received a second intravitreal injection of 25 mg of triamcinolone acetonide 3.1 to 18 months after the first injection. Mean +/- SD follow-up time after the second injection was 5.2 +/- 3.6 months (median, 5.3 months). A control group included 24 patients with exudative age-related macular degeneration who did not receive treatment for their maculopathy. The main outcome measures were visual acuity and intraocular pressure. RESULTS: In the study group, mean +/- SD visual acuity increased significantly (P =.005 and P =.003, respectively) from 0.17 +/- 0.11 to 0.32 +/- 0.26 and from 0.15 +/- 0.14 to 0.23 +/- 0.19, respectively, after the first and second injections. An increase in visual acuity was found for 10 patients (77%) after the first and second injections. In the control group, visual acuity did not vary significantly during follow-up (P =.81). The difference in change in visual acuity between the study group and control group was significant (P =.01 [Snellen lines] and P =.05 [logMAR units]). The peak in visual acuity and, in a chronologically parallel manner, the peak in intraocular pressure elevation occurred 2 to 5 months after each injection. CONCLUSIONS: Repeated intravitreal injection of 25 mg of triamcinolone acetonide may lead to an increase in visual acuity in patients with exudative age-related macular degeneration, with the peak in visual acuity and intraocular pressure elevation occurring about 2 to 5 months after each injection. SN - 0003-9950 UR - https://www.unboundmedicine.com/medline/citation/14769599/Intravitreal_reinjection_of_triamcinolone_for_exudative_age_related_macular_degeneration_ L2 - https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/archopht.122.2.218 DB - PRIME DP - Unbound Medicine ER -